Αποτελέσματα Αναζήτησης
26 Ιουν 2018 · The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity...
26 Ιουν 2018 · A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.
The Polio Eradication Strategy 2022–2026 reflects the kind of integrated approaches that will be required to deliver on the promise of eradication. Through this new strategy, we believe the GPEI has re-envisioned its relationship with governments, deepened its
11 Φεβ 2023 · First, setting a time horizon for the elimination of polio vac-cines discourages manufacturers from investing in research and development of better vaccines. There are several options for such ...
8 Μαρ 2024 · To boost the immune system’s response, researchers at the NCI Center for Cancer Research’s Neuro-Oncology Branch (NOB) have created a cancer vaccine that can activate immune cells to recognize and attack glioblastomas.
16 Μαΐ 2016 · Using a modified form of poliovirus that has been altered to eliminate harm, the therapy preferentially attacks cancer cells, which have an abundance of receptors that work like magnets to attract the poliovirus.
10 Φεβ 2020 · The Phase I trial, conducted at The Preston Robert Tisch Brain Tumor Center at Duke Cancer Institute, showed encouraging results. Overall survival among patients who received PVSRIPO plateaued at 21 percent at 24 to 36 months and appears to last for up to five years.
